INVESTIGATIONAL DRUGS FOR
Volunteers & Patients
We empower study participants by educating them about clinical research, enabling them to make informed decisions regarding study participation.
NEW POSSIBILITIES FOR
Investigators
Clinilabs collaborates with investigator sites worldwide to conduct clinical trials that lead to new drug approvals. Become an investigator in our global network!
Experts in CNS Therapeutics
We specialize in a wide range of therapeutic areas with a focus on CNS trials conducted at investigator sites on five continents.
Sleep Disorders
Psychiatric Disorders
Neurological Disorders
New Treatments. New Possibilities.
The mid-sized clinical CRO specializing in first-in-human to Phase 3 trials, with a global core laboratory.
Connect With Us
Connect with us online, or come visit us at
an upcoming industry event!
CNS Summit 2019
October 31 - November 3 at The Boca Raton Resort & ClubACNP Annual Meeting 2019
December 8 @ 8:00 am - December 11 @ 5:00 pm at Hilton Orlando Bonnet Creek38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 @ 8:00 am - January 16, 2020 @ 5:00 pm at The Westin St. Francis San Francisco on Union Square
Latest News & Updates
Clinilabs Drug Development Corporation and SureClinical Announce Global Lunch & Learn Series for Clinical Operations
Clinilabs Drug Development Corporation, a CNS-focused contract research organization, and SureClinical, a global provider of innovative cloud solutions for the health sciences market, are sponsoring a global Lunch & Learn series demonstrating how sponsors can [...]
Epilepsy Monitoring Unit
Clinilabs Drug Development Corporation is pleased to announce that it has established a 6-bed epilepsy monitoring unit at its New York City facility. The facility, which boasts a 50-bed inpatient capacity for clinical studies, offers [...]
CNS Sites of the Future
At this year’s CNS Summit, held in Boca Raton, Florida November 1 – 4 2017, attendees participated in a panel discussion that considered the characteristics that investigator sites will have in the future. Many of [...]